What Cloudbreak Pharma’s Phase 2 FDA meeting reveals about late-stage risk in ophthalmic drug development
Find out how Cloudbreak Pharma’s Phase 2 FDA meeting reshapes late-stage risk for CBT-004 and what it signals for ophthalmic drug development.
How urcosimod’s FDA compassionate use authorization reshapes development risk in ocular neuropathic pain
FDA allows compassionate use of urcosimod for neuropathic corneal pain. Read how this decision reshapes regulatory, clinical, and development risk.